Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine

被引：0
|
作者：
Ailani, J. [1 ]
Gandhi, P. [2 ]
Lalla, A. [3 ]
Singh, R. B. Halker [4 ]
McAllister, P. [5 ]
Smith, J. H. [6 ]
Dabruzzo, B. [2 ]
Chalermpalanupap, N. [2 ]
Nahas, S. J. [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] AbbVie, Madison, NJ USA
[3] AbbVie, Irvine, CA USA
[4] Mayo Clin, Scottsdale, AZ USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] AbbVie, N Chicago, IL USA
[7] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P051
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
    Ailani, Jessica
    Gandhi, Pranav
    Lalla, Anjana
    Singh, Rashmi Halker
    McAllister, Peter
    Smith, Jonathan H.
    Dabruzzo, Brett
    Chalermpalanupap, Natty
    Kelton, Kari
    Nahas, Stephanie J.
    HEADACHE, 2024, 64 (10): : 1253 - 1263
  • [2] Atogepant for the Preventive Treatment of Migraine
    Ailani, Jessica
    Lipton, Richard B.
    Goadsby, Peter J.
    Guo, Hua
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08): : 695 - 706
  • [3] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, R.
    Ashina, M.
    Tassorelli, C.
    Martin, V.
    Yu, S. Y.
    Nagy, K.
    Schwefel, B.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [4] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, Richard B.
    Ashina, Messoud
    Tassorelli, Cristina
    Martin, Vincent
    Yu, Sung Y.
    Nagy, Krisztian
    Schwefel, Brittany
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 31 - 32
  • [5] Daily atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 118 - 118
  • [6] Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
    Blair, Hannah A.
    CNS DRUGS, 2023, 37 (03) : 255 - 265
  • [7] Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
    Hannah A. Blair
    CNS Drugs, 2023, 37 : 255 - 265
  • [8] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Ferreira, De Abreu R.
    Trugman, J.
    HEADACHE, 2023, 63 : 117 - 117
  • [9] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [10] Comparison of atogepant vs rimegepant in refractory chronic migraine: A retrospective analysis
    Baek, William
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
12345